Will Novartis’ Tekturna Be Buoyed By Category Captainship?
Executive Summary
The performance of Novartis' newly approved hypertension therapy Tekturna will be a good test of the company's "category captainship" program, which has focused on establishing Novartis as a leader in targeted disease areas